Document:

<PAGE>   1

                                                                   EXHIBIT 10.38

                            INDEMNIFICATION AGREEMENT

        THIS INDEMNIFICATION AGREEMENT ("Agreement") is made and entered into as
of the date last written below, by and between IRORI ("IRORI") and SOKYMAT, S.A.
("Sokymat") (collectively, IRORI and Sokymat shall be referenced as the
"Parties").

                                    RECITALS

        WHEREAS, the Parties are defendants in Trovan, Ltd. et al. y. Sokymat,
S.A. et al., United States District Court for the Central District of California
Case No. CV 97-4585 MRP (AJWx), filed on or about June 23, 1997, (the "Action");

        WHEREAS, Plaintiffs allege in the Action, among other things, that IRORI
is liable for patent infringement as a result of IRORI's sale and/or
distribution of product manufactured by Sokymat;

        WHEREAS, IRORI desires to have Sokymat defend, indemnify and hold IRORI
harmless to the full extent allowable by law is connection with the facts,
circumstances and patent infringement (or infringement related) claims asserted
in the Action in connection with U.S. Patent 5,281,855 (the "'855 Patent") and
U.S. Patent 5,572, 410 (the "'410 Patent"); and

        WHEREAS, Sokymat is willing to defend, indemnify and hold IRORI harmless
to the full extent allowable by law in connection with the facts, circumstances
and patent infringement (or infringement related) claims asserted in the Action
in connection with the `855 Patent and `410 Patent on the condition that Sokymat
be allowed to control IRORI's defense and settlement of the action.

                                    AGREEMENT

        NOW, THEREFORE, in consideration of these promises and covenants
contained herein it is hereby agreed by and between the parties hereto as
follows:

        1. Sokymat shall indemnify, defend and hold IRORI harmless to the full
extent allowable by law in connection with the facts, circumstances and patent
infringement (or infringement-related) claims asserted in the Action in
connection with the `855 Patent and the `410 Patent, including without
limitation and to the full extent allowable indemnifying, defending and holding
IRORI harmless against any and all liabilities, demands, causes of action,
costs, expenses, attorneys' fees, damages, exemplary awards (such as double or
treble damages or attorneys' fees awards), settlements and obligations of every
kind and nature, at law, in equity or otherwise (collectively, the "Indemnified
Claims").

        2. This Agreement shall not provide indemnification in connection with
the Action against any acts which cannot by law be indemnified, such as: (a)
acts done by IRORI prior to the effective date of this Agreement which
constitute a felony (California Civil Code section 2774); or (b) acts done by
IRORI after the effective date of this Agreement if known by IRORI to be
unlawful at the time of doing such acts (California Civil Code section 2773). To
the extent that there is a final binding determination in the Action that IRORI
committed any acts which cannot by law be indemnified, this Agreement shall not
cover such acts; however, in such case

<PAGE>   2

IRORI shall still be entitled pursuant to this Agreement to be indemnified,
defended and held harmless by Sokymat to the full extent allowable by law in
connection with in the Action.

        3. Sokymat shall control the defense of IRORI in the Action. Sokymat
shall bear all fees and expenses incurred by Sokymat in connection with
investigating, preparing to defend, or defending IRORI in connection with the
Action. IRORI shall have the right to participate in its defense in connection
with the Action, including without limitation the right to employ separate
counsel at IRORI's expense; provided, however, that control over final decision
making shall remain with Sokymat. IRORI shall have the right to review all court
filings, correspondence, discovery, deposition transcripts, and other documents
related to Sokymat's defense of IRORI in connection with the Action and all such
documents shall be provided to IRORI by Sokymat at Sokymat's expense.

        4. IRORI agrees to provide to Sokymat all information within IRORI's
possession, custody, or control which is requested by Sokymat in connection with
the investigating, preparing to defend or defending the Action and any other
assistance that may be reasonably required in connection with the investigating,
preparing to defend or defending IRORI in connection with the Action.

        5. The Parties agree to take such other and further steps as may be
necessary or appropriate to assure that the intent of this Agreement is
effectuated.

        6. Each Party specifically denies the claims asserted in the Action.
This Agreement is not intended to reflect in any way either the merits of any of
those claims or that there has been any wrongdoing by any Party, and is intended
to facilitate the defense of the Action while assuring that IRORI is
indemnified, defended and held harmless in connection therewith. The promises in
this Agreement shall not be construed to be an admission of any liability or
obligation whatsoever by any Party to any other Party to this Agreement or to
any other person whomsoever.

        7. This Agreement, any drafts thereof, and any related documents are
intended to be confidential, to facilitate the common defense of the Parties,
and to be subject to the Parties' joint defense agreement set forth in the
letter dated September 26, 1997 addressed to Michael R. Adele, Esq., and
executed by counsel for the Parties.

        8. The only representations and warranties on which the Parties have
relied in entering this Agreement are those set forth in writing within this
Agreement.

        9. It is the intention of the Parties, through this Agreement, that
Sokymat indemnify, defend and hold IRORI harmless to the greatest extent
allowable by law, and that all provisions herein be construed and enforced in
accordance with that intention. This Agreement is not intended to provide
indemnification against acts which cannot by law be the enforceable subject of
an indemnification agreement, such as: (a) acts done by IRORI prior to the
effective date of this Agreement which constitute a felony (California Civil
Code section 2774); or (b) acts done by IRORI after the effective date of this
Agreement if known by IRORI to be unlawful at the time of doing such acts
(California Civil Code section 2773).

                                       2
<PAGE>   3

        10. The Parties acknowledge that each of the Parties have participated
in the drafting and negotiation of this Agreement. For purposes of interpreting
this Agreement, each provision, paragraph, sentence and word herein shall be
deemed to have been jointly drafted by the Parties. The Parties intend for this
Agreement to be construed and interpreted neutrally in accordance with the plain
meaning of the language contained herein, and not presumptively construed
against any actual or purported drafter of any specific language contained
herein.

        11. This Agreement shall bind the successors and assigns of each Party,
and inure to the benefit of each Party, its agents, directors, officers,
employees, attorneys, successors and assigns.

        12. The Agreement contains the entire agreement between the Parties
hereto and constitutes the complete, final and exclusive embodiment of their
agreement with respect to the subject matter hereof. All prior or
contemporaneous agreements, understandings, representations and statements, oral
or written, are merged into and superseded by this Agreement. No claimed
additions to or modifications or amendments of this Agreement, nor any claimed
waiver of any of its terms or conditions, shall be effective unless in writing
and signed by the Party against whom the same may be asserted.

        13. This Agreement shall be deemed to have been entered into, and shall
be construed and enforced, in accordance with the laws of the State of
California as applied to contracts made and to be performed entirely in
California.

        14. With regard to enforcement of this Agreement, the Parties consent to
the jurisdiction of the state of federal courts of California, which the Parties
agree shall constitute the exclusive forum for enforcement of this Agreement;
provided, however, that any judgment rendered by a California court may be
enforced outside of California resort to whatever court or tribunal may be
necessary or appropriate.

        15. If any term, clause or provision in this Agreement shall be found to
be unenforceable, that term, clause or provision shall be struck and all
remaining terms, clauses and provisions of the Agreement shall be valid and
enforceable.

        16. Whenever the text hereof requires, the use of the singular noun
shall include the appropriate plural noun and vice-versa.

        17. Any statements, communications or notices to be provided pursuant to
this Agreement shall be sent in writing to the attention of the persons
indicated below, until such time as notice of any change of person to be
notified or change of address is forwarded to all Parties:

                       SOKYMAT, S.A.:

                       James A. Oliff, Esq.
                       Oliff & Berridge
                       700 South Washington Street
                       Alexandria, VA 22314
                       Facsimile:  (703) 836-2787

                                       3
<PAGE>   4

                       IRORI:

                       Michael R. Adele, Esq.
                       Cooley Godward LLP
                       4365 Executive Drive, Suite 1100
                       San Diego, CA 92121
                       Facsimile:  (619) 453-3555

        18. This Agreement may be executed in two or more counterparts, each of
which shall be deemed an original all of which together shall constitute one and
the same instrument.

        IN WITNESS WHEREOF the Parties have duly authorized and caused this
Agreement to be executed on the date set forth below.

ACCEPTED AND AGREED BY:

                                                 Sokymat S.A.

Dated:  April 19, 1999                           /s/ Herbert Thyssen
        ----------------------------             ----------------------------
                                                 By:  Herbert Thyssen
                                                 Its: Managing Director

                                                 IRORI

Dated:  April 19, 1999                           /s/ Jack Fitzpatrick
        ----------------------------             ----------------------------
                                                 By:  Jack Fitzpatrick
                                                 Its: CFO

                                       4<PAGE>   1
                                                                   EXHIBIT 10.39

                          STRATEGIC ALLIANCE AGREEMENT

                                     BETWEEN

                          BRISTOL-MYERS SQUIBB COMPANY

                                       AND

                                      IRORI

                            DATED AS OF MAY 22, 1998

<PAGE>   2

                                TABLE OF CONTENTS

<TABLE>
<CAPTION>
                                                                                          Page
                                                                                          ----
<S>     <C>                                                                               <C>
1.      DEFINITIONS.........................................................................1
        1.1    "Acceptance Date"............................................................1
        1.2    "Affiliate"..................................................................1
        1.3    "BMS Resins".................................................................2
        1.4    "Development Committee"......................................................2
        1.5    "Development Milestone"......................................................2
        1.6    "Effective Date".............................................................2
        1.7    "Enhancement"................................................................2
        1.8    "Enhancement Specifications".................................................2
        1.9    "Facility"...................................................................2
        1.10   "Initial Delivery Deadline"..................................................2
        1.11   "NanoKan"....................................................................2
        1.12   "NanoKan Specifications".....................................................3
        1.13   "Party"......................................................................3
        1.14   "Purchase Price".............................................................3
        1.15   "Right and License"..........................................................3
        1.16   "Software"...................................................................3
        1.17   "System".....................................................................3
        1.18   "System Specifications"......................................................3
        1.19   "Third Party"................................................................3
        1.20   "Update".....................................................................3

2.      MANUFACTURE; DELIVERY; OPTION.......................................................3
        2.1    Generally....................................................................4
        2.2    Satisfaction of Development Milestones, etc.; Acceptance; Rejection..........4
        2.3    Delivery; Installation.......................................................5
        2.4    Identification; Passage of Title.............................................5
        2.5    Option to Purchase Additional System.........................................5

3.      DEVELOPMENT COMMITTEE...............................................................7
        3.1    Members......................................................................7
        3.2    Responsibilities.............................................................7
        3.3    Meetings.....................................................................7
        3.4    Decisions....................................................................8
        3.5    Term.........................................................................8
        3.6    Expenses.....................................................................8

4.      INITIAL SYSTEM PURCHASE PRICE; PAYMENT..............................................8
        4.1    Initial System Purchase Price................................................8
        4.2    Payment Schedule.............................................................9
        4.3    Mode of Payment; Taxes.......................................................9

5.      INTELLECTUAL PROPERTY; UPDATES......................................................9
        5.1    Invention Ownership..........................................................9
</TABLE>

                                       i
<PAGE>   3

                                TABLE OF CONTENTS
                                   (Continued)

<TABLE>
<CAPTION>
                                                                                          Page
                                                                                          ----
<S>     <C>                                                                               <C>
        5.2    Title Does Not Pass; Right and License.......................................9
        5.3    Updates.....................................................................10
        5.4    Enhancements................................................................10
        5.5    Installation................................................................11
        5.6    Source Code.................................................................11

6.      SUPPORT; TRAINING..................................................................12
        6.1    Support and Maintenance.....................................................12
        6.2    Training....................................................................12

7.      SUPPLY AND PURCHASE................................................................12
        7.1    Initial Obligations.........................................................12
        7.2    Requirements................................................................13
        7.3    Orders......................................................................13
        7.4    Delivery....................................................................13
        7.5    Quality Control.............................................................14
        7.6    Acceptance; Rejection.......................................................14
        7.7    Interim Replacement.........................................................14
        7.8    Replacement of BMS Resins...................................................15
        7.9    Invoicing; Payment..........................................................15
        7.10   Allocation..................................................................15
        7.11   Right to Manufacture........................................................16
        7.12   BMS's Right to Manufacture..................................................16

8.      REPRESENTATIONS AND WARRANTIES; COVENANTS..........................................16
        8.1    Representations and Warranties of Both Parties..............................16
        8.2    Representations and Warranties of IRORI.....................................17
        8.3    Limited Right of Repair.....................................................17
        8.4    Disclaimer of Warranty......................................................18
        8.5    Covenants of BMS............................................................18

9.      THIRD PARTIES......................................................................18
        9.1    Semi-Exclusivity............................................................18
        9.2    Most Favored Nation.........................................................18
        9.3    Audit Request...............................................................19

10.     INDEMNIFICATION....................................................................19
        10.1   Obligation to Indemnify.....................................................20
        10.2   Notice......................................................................20
        10.3   Complete Indemnification....................................................20
        10.4   Insurance...................................................................20
        10.5   Partial Limitation on IRORI Indemnity.......................................20
</TABLE>

                                       ii
<PAGE>   4

                                TABLE OF CONTENTS
                                   (Continued)

<TABLE>
<CAPTION>
                                                                                          Page
                                                                                          ----
<S>     <C>                                                                               <C>
11.     CONFIDENTIALITY....................................................................21
        11.1   Confidential Information....................................................21
        11.2   Permitted Disclosures.......................................................21
        11.3   Remedies....................................................................21

12.     TERM; TERMINATION..................................................................22
        12.1   Term........................................................................22
        12.2   Termination by BMS..........................................................22
        12.3   Breach......................................................................22
        12.4   Effect of Termination.......................................................23
        12.5   Accrued Rights, Surviving Obligations.......................................23

13.     FORCE MAJEURE......................................................................24
        13.1   Events of Force Majeure.....................................................24

14.     MISCELLANEOUS......................................................................24
        14.1   Non-Solicitation............................................................24
        14.2   Relationship of Parties.....................................................24
        14.3   Assignment..................................................................25
        14.4   Binding Effect..............................................................25
        14.5   Further Actions.............................................................25
        14.6   Costs and Expenses..........................................................25
        14.7   Inconsistency...............................................................25
        14.8   Notice......................................................................26
        14.9   Use of Name.................................................................26
        14.10  Public Announcements........................................................26
        14.11  Waiver......................................................................27
        14.12  Severability................................................................27
        14.13  Amendment...................................................................27
        14.14  Governing Law...............................................................27
        14.15  Arbitration.................................................................27
        14.16  Limitation on Liability.....................................................28
        14.17  Entire Agreement............................................................28
        14.18  Counterparts................................................................28
        14.19  Descriptive Headings........................................................28
</TABLE>

                                    EXHIBITS

EXHIBIT A  SYSTEM AND NANOKAN SPECIFICATIONS AND MILESTONES

EXHIBIT B  PROGRESS PAYMENT SCHEDULE

EXHIBIT C  DESCRIPTION OF INSURANCE COVERAGE

                                      iii
<PAGE>   5

                          STRATEGIC ALLIANCE AGREEMENT

        THIS STRATEGIC ALLIANCE AGREEMENT (this "Agreement") dated as of May 22,
1998 by and between Bristol-Myers Squibb Company, a corporation duly organized
and existing under the laws of the State of Delaware, having offices at P.O. Box
4000, Route 206 and Province Line Road, Princeton, New Jersey 08543-4000, for
and on behalf of itself and its Affiliates ("BMS"), and IRORI, a corporation
duly organized and existing under the laws of the State of California, having
offices at 11149 North Torrey Pines Road, La Jolla, California 92037-1030
("IRORI").

                             PRELIMINARY STATEMENTS

        A. BMS is a pharmaceutical company that engages in the discovery and
development of new drug products.

        B. IRORI has developed directed sorting combinatorial chemistry systems
that use microreactors and miniature electronic tags.

        C. BMS wishes to purchase from IRORI and secure a license from IRORI
with respect to, and IRORI wishes to manufacture and sell to BMS and grant a
license to BMS with respect to, a System, upon the terms and conditions set
forth in this Agreement.

        D. In addition, BMS wishes to purchase from IRORI, and IRORI wishes to
sell to BMS, a quantity of NanoKans, also upon the terms and conditions set
forth in this Agreement.

        E. In conjunction with the execution of this Agreement, the Parties are
entering into that certain Series D Preferred Stock Purchase Agreement, dated as
of the Effective Date (the "Stock Purchase Agreement"), and such other
agreements as are contemplated thereby.

        NOW, THEREFORE, in consideration of the foregoing Preliminary Statements
and the mutual covenants and agreements of the Parties contained in this
Agreement, the Parties agree as follows:

1. DEFINITIONS.

        As used in this Agreement, the following terms will have those meanings
set forth in this Section 1 unless the context dictates otherwise.

        1.1 "Acceptance Date" shall mean, with respect to a System or an
Enhancement, the date on which BMS accepts such System or Enhancement in
accordance with Section 2.2 or 5.4, as the case may be.

        1.2 "Affiliate", with respect to any party, shall mean any entity
controlling, controlled by, or under common control with, such Party (but only
so long as such control relationship exists). For these purposes, "control"
shall refer to (i) the possession, directly or indirectly, of the power to
direct the management or policies of an entity, whether through the ownership of
voting

<PAGE>   6

securities, by contract or otherwise or (ii) the ownership, directly or
indirectly, of at least 50% of the voting securities or other ownership interest
of an entity.

        1.3 "BMS Resins" shall have the meaning assigned thereto in Section
7.1(b).

        1.4 "Development Committee" shall have the meaning assigned thereto in
Section 3.1.

        1.5 "Development Milestone" shall mean each of the milestones set forth
on Exhibit A attached.

        1.6 "Effective Date" shall mean the date first written above.

        1.7 "Enhancement" shall mean any upgrade or improvement to the System
that materially improves its utility, efficiency or efficacy and that is not
primarily intended to correct or avoid errors, malfunctions or defects in the
System.

        1.8 "Enhancement Specifications" shall mean, with respect to any
Enhancement, written specifications that set forth with specificity the quality
and degree of improvement to the System that such Enhancement provides.

        1.9 "Facility" shall mean a facility in the continental United States
selected by BMS at its sole discretion pursuant to Section 2.3.

        1.10 "Initial Delivery Deadline"shall mean   ***   .

        1.11 "NanoKan" shall mean IRORI's proprietary microreactor for solid
phase synthesis that conforms to the NanoKan Specifications.

        1.12 "NanoKan Specifications" shall mean the specifications set forth in
Exhibit A attached which relate to NanoKans (including, without limitation, the
percentage of BMS Resins supplied to IRORI for incorporation into a shipment(s)
of NanoKans that actually is incorporated into such shipment(s)), as may be
amended by the Development Committee from time to time.

        1.13 "Party" shall mean BMS or IRORI and, when used in the plural, shall
mean BMS and IRORI.

        1.14 "Purchase Price" shall mean the Initial System Purchase Price (as
such term is defined in Section 4.1), the Second System Purchase Price (as such
term as defined in Section 2.5) and the Enhancement Purchase Price(s) (as such
term is defined in Section 5.4), either individually or collectively, as context
dictates.

        1.15 "Right and License" shall have the meaning assigned thereto in
Section 5.2.

        1.16 "Software" shall mean all of the software adapted or incorporated
into the system from time to time.

*** Portions of this page have been omitted pursuant to a request for
    Confidential Treatment and filed separately with the Commission

                                       2
<PAGE>   7

        1.17 "System" shall mean IRORI's proprietary NanoKan Reactor System,
including all hardware, equipment, Software and other components and any Updates
or Enhancements provided to BMS pursuant to Section 5.3 or 5.4. Except to the
extent context dictates otherwise, "System" shall include both the Initial
System (as defined in Section 2.1) and the Second System (as defined in Section
2.5).

        1.18 "System Specifications" shall mean the specifications set forth on
Exhibit A attached relating to the System, as may be amended by the Development
Committee from time to time.

        1.19 "Third Party" shall mean any Person who or which is neither a Party
nor an Affiliate of a Party.

        1.20 "Update" shall mean with any update, upgrade or improvement to the
System other than Enhancements.

2. MANUFACTURE; DELIVERY; OPTION.

        2.1 Generally. On or before the Initial Delivery Deadline, IRORI shall
manufacture, deliver and install at the Facility, in accordance with the System
Specifications and the terms of this Agreement, one System (the "Initial
System"). During the period between the Effective Date and the date on which the
initial System is delivered to the Facility, IRORI shall use its best commercial
efforts to diligently fulfill its obligations under this Agreement and to
satisfy each Development Milestone in a timely and expeditious manner and by the
target completion date set forth on Exhibit A with respect to such Development
Milestone.

        2.2 Satisfaction of Development Milestones, etc.; Acceptance; Rejection.

               (a) (i) IRORI shall give BMS notice promptly after IRORI believes
that it has satisfied each Development Milestone with respect to the Initial
System. For a period of *** (a "Testing Period") after the date of each such
notice, BMS shall have the right to test the Initial System, as it then exists,
at IRORI's site to verify that such Development Milestone has been satisfied
(using the Development Milestone Criteria). BMS shall use reasonable efforts to
expedite the performance of such testing.

                      (ii) If, prior to the expiration of any Testing Period,
BMS fails to notify IRORI that such Development Milestone has not been
satisfied, then such Development Milestone shall be deemed to have been
satisfied.

                      (iii) If such testing indicates that such Development
Milestone has not been satisfied, then prior to the expiration of the Testing
Period, BMS shall notify IRORI of such non-satisfaction in sufficient detail to
allow IRORI to attempt to remedy it. During the   ***   period following receipt
of any such notice, IRORI shall use its best commercial efforts to satisfy such
Development Milestone. If BMS reasonably determines, within  ***  after such ***
period, that such Development Milestone still has not been satisfied, then BMS
shall he excused

*** Portions of this page have been omitted pursuant to a request for
    Confidential Treatment and filed separately with the Commission

                                       3
<PAGE>   8

temporarily from its obligation to make the payment of the Initial System
Purchase Price that pertains to such Development Milestone under Section 4.2,
until such Development Milestone has been achieved. If BMS fails to notify IRORI
that such Development Milestone has not been satisfied prior to the expiration
of such  ***  period, then such Development Milestone shall be deemed to have
been satisfied.

               (b) (i) On or before the Initial Delivery Deadline, IRORI shall
manufacture the Initial System and have it ready at IRORI's factory for testing
pursuant to this Section 2.2(b), IRORI shall give BMS notice (a "Readiness
Notice") promptly after IRORI believes that the Initial System has been
completed and is ready for delivery. BMS shall have the right, as promptly as
possible after the date of each Readiness Notice, and in any event not more than
*** after the date of such notice, to test the Initial System to verify that the
Initial System conforms to the System Specifications (using testing protocols
developed by the Development Committee).

                      (ii) If, prior to the expiration of such  ***  period, BMS
fails to notify IRORI that the Initial System does not conform to the System
Specifications, then the Initial System shall be deemed to conform to the System
Specifications, and BMS shall be deemed to have accepted the Initial System.

                      (iii) If such testing indicates that the Initial System
does not conform to the System Specifications, then prior to the expiration of
such  ***  period, BMS shall notify IRORI of such non-conformity in sufficient
detail to allow IRORI to attempt to remedy it. During the  ***  period following
receipt of any such notice, IRORI shall use its best commercial efforts to bring
the Initial System into conformity with the System Specifications. If BMS
reasonably determines, within  *** after such  ***  period, that the Initial
System still does not conform to the System Specifications, then BMS shall be
entitled to reject the Initial System by notice to IRORI, in addition to any
other rights BMS may have under this Agreement, at law or in equity. If BMS
fails to notify IRORI that the Initial System does not conform to the System
Specifications prior to the expiration of such  ***  period; then the Initial
System shall be deemed to conform to the System Specifications, and BMS shall be
deemed to have accepted the Initial System.

               (c) Notwithstanding Section 14.15, any dispute arising between
the Parties as to whether a Development Milestone has been satisfied or the
Initial System conforms to the System Specifications shall finally be determined
by the Development Committee in accordance with Section 3.4.

        2.3 Delivery; Installation.

               (a) Within  ***  after BMS's receiving a Readiness Notice with
respect to the Initial System, BMS shall notify IRORI of the location of the
Facility and of any special delivery instructions. The Parties shall cooperate
in coordinating the delivery and installation of the

*** Portions of this page have been omitted pursuant to a request for
    Confidential Treatment and filed separately with the Commission

                                       4
<PAGE>   9

Initial System at the Facility. IRORI shall install the Initial System at the
Facility in accordance with BMS's reasonable instructions and the System
Specifications.

               (b) BMS shall have the right, as promptly as possible after
installation of the Initial System but in any event not more than *** after
IRORI's installation of the initial System at the Facility, to verify that the
Initial System continues to conform to the System Specifications. To the extent
it does not, IRORI shall promptly bring the Initial System into such conformity.

        2.4 Identification; Passage of Title. The Initial System shall be
identified to this Agreement as of the Effective Date. IRORI shall bear the risk
of any loss, deterioration or damage until the Initial System has been delivered
and installed at the Facility in accordance with the term of this Agreement.
Except as provided in Section 5.2, title to the Initial System shall pass to BMS
upon delivery and installation of the Initial System at the Facility in
accordance with the terms of this Agreement.

        2.5 Option to Purchase Additional System.

               (a) At any time prior to   ***    ***  , BMS shall have an option
to purchase a second System (the "Second System"). The total purchase price (the
"Second System Purchase Puce") payable by BMS in consideration of IRORI's
manufacture, delivery and installation of the Second System by IRORI, and the
Right and License with respect to the Second System that will be effective upon
the Acceptance Date with respect thereto, shall be   ***  ; provided, however,
that if the Acceptance Date with respect to the Second System is delayed more
than   ***   (such period, as may be extended as provided below, the "Grace
Period") after the Second Delivery Deadline (as defined herein), the Second
System Purchase Price shall be reduced by   ***   (calculated without regard to
any previous reductions) for each   ***   (of portion thereof) that such
Acceptance Date is delayed beyond the Grace Period, except to the extent that
BMS causes any such delay. The Parties acknowledge and agree that BMS's testing
of the Second System in accordance with Section 2.2 shall not constitute delay.
If the Grace Period has not expired at the time IRORI sends a Readiness Notice
with respect to the Second System, then the Grace Period shall be extended (or,
as the case may be, any period of delay of the Acceptance Date with respect to
the Second System beyond the expiration of the Grace Period shall be tolled),
day-for-day, for each day that elapses between BMS's receipt of any Readiness
Notice and completion of BMS's inspection of the Second System pursuant to
Section 2.2(b)(i) (as such Section relates to the Second System pursuant to
Section 2.5(d)). BMS shall notify IRORI Promptly of the completion of any such
inspection.

               (b) BMS may exercise such option by delivering a notice (the
"Option Exercise Notice") to IRORI. The Option Exercise Notice shall set forth
the date on which BMS expects IRORI to deliver a Readiness Notice with respect
to the Second System (the "Second Delivery Deadline"), which shall not be sooner
than        ***         ***

*** Portions of this page have been omitted pursuant to a request for
    Confidential Treatment and filed separately with the Commission

                                       5
<PAGE>   10

***   Following receipt of an Option Exercise Notice, IRORI shall use its best
commercial efforts to diligently manufacture, deliver and install the Second
System in a timely and expeditious manner. The Second System shall be identified
to this Agreement as of the date of the Option Exercise Notice.

               (c) BMS shall pay the Second System Purchase Price according to
the following schedule:

                      (i)   ***   shall be paid in conjunction with delivery of
the Option Exercise Notice;

                      (ii)   ***   shall be paid within 45 days after the
Acceptance Date with respect to the Second System; and

                      (iii)   ***   shall be paid within 45 days after BMS's
verification, pursuant to Section 2.3(b), that the Second System conforms to the
System Specifications.

In the event that BMS rejects the Second System pursuant to Section 2.2(b)(iii),
BMS shall be excused from making any further payment of the Second System
Purchase Price.

               (d) Except as expressly set forth in this Section 2.5, Sections
2.2(b), 2.3 and 2.4 shall apply to IRORI's manufacture, delivery and
installation of the Second System as well as to its manufacture, delivery and
installation of the Initial System; provided, however, that the   ***   periods
referred to in Sections 2.2(b) and 2.3(b) shall be reduced to   ***   with
respect to the Second System, so long as IRORI shall have given BMS at least ***
prior notice as to the date on which the Readiness Notice with respect to the
Second System will be delivered.

3. DEVELOPMENT COMMITTEE.

        3.1 Members. The Parties shall establish the Development Committee (the
"Development Committee"), which shall be comprised of six members, three
representatives designated by each Party. Members of the Development Committee
may be represented at any meeting by a designee appointed by such member for
such meeting. The chairperson of the Development Committee shall be designated
annually on an alternating basis between the Parties. The initial chairperson
shall be selected by BMS. The Party not designating the chairperson shall
designate one of its representative members as secretary to the Development
Committee for such year. Each Party shall be free to change its representative
members, on notice to the other Party.

        3.2 Responsibilities. The Development Committee shall be responsible
for:

               (a) developing, reviewing and modifying, from time to time,
testing protocols for all Systems and Enhancements;

               (b) reviewing and modifying, from time to time, the System
Specifications, Enhancement Specifications and NanoKan Specifications;

*** Portions of this page have been omitted pursuant to a request for
    Confidential Treatment and filed separately with the Commission

                                       6
<PAGE>   11

               (c) developing, reviewing and modifying, from time to time,
criteria (the "Development Milestone Criteria") for determining whether each of
the Development Milestones has been satisfied; and

               (d) overseeing the testing of all Systems prior to the delivery
thereof.

The Development Committee shall use its best efforts to develop the testing
protocols for the Initial System and the Development Milestone Criteria not
later than 90 days after the Effective Date.

        3.3 Meetings. The Development Committee shall meet at such times and in
such places as the Parties shall agree. Meetings may also be called by either
Party, on 10 days' written notice to the other unless such notice is waived by
the Parties. The meetings shall alternate between the offices of the Parties
unless the Parties otherwise agree. The chairperson shall be responsible for
sending notices of meetings to all members. The Development Committee may also
convene or be polled or consulted from time to time by means of
telecommunications, video conferences or correspondence, as deemed necessary or
appropriate.

        3.4 Decisions.

               (a) All decisions of the Development Committee shall be made by
unanimous agreement of the members (or their designees) present in person or by
telephone at any meeting, provided that at least one representative of each
Party is present at such meeting.

               (b) In the event that unanimity cannot be reached by the
Development Committee with respect to a matter that is subject to its
decision-making authority, then the matter shall be referred for further review
and resolution to the Vice President, Chemistry, at BMS, or such other similar
position designated by BMS from time to time, and the Vice President, Business
Development, at IRORI, or such other similar position designated by IRORI from
time to time. Such designated officers of each Party shall use reasonable
efforts to resolve the matter within 30 days after the matter is referred to
them. If they cannot resolve the matter within 30 days, the matter shall be
referred for further review and resolution to the President of BMS's
Pharmaceutical Research Institute, or such other similar position designated by
BMS from time to time, and IRORI's Chief Executive Officer, or such other
similar position designated by IRORI from time to time. Such designated officers
of each Party shall use reasonable efforts to resolve the matter within 30 days
after the matter is referred to them. If they cannot resolve the matter within
30 days, then the matter shall be decided by the President of BMS's
Pharmaceutical Research Institute, or such other similar position designated by
BMS from time to time, in good faith, giving appropriate consideration to the
reasonable business, scientific and technical feasibility concerns of IRORI.

               (c) All decisions of the Development Committee or the designated
officer(s) of the Party(ies) made in accordance with the procedures set forth in
this Section 3.4 shall be final and binding upon the Parties and shall only he
appealable by either of the Parties if not made in good faith or, to the extent
applicable, with appropriate consideration of reasonable business, scientific
and technical feasibility concerns.

                                       7
<PAGE>   12

        3.5 Term. The Development Committee shall exist for such period as
necessary to perform the responsibilities assigned to it under this Agreement.

        3.6 Expenses. Each Party shall be responsible for all travel and related
costs for its representatives to attend meetings of, and otherwise participate
on, the Development Committee.

4. INITIAL SYSTEM PURCHASE PRICE; PAYMENT.

        4.1 Initial System Purchase Price. The total purchase price (the
"Initial System Purchase Price") payable by BMS in consideration of IRORI's
manufacture, delivery and instillation of the Initial System by IRORI, and the
Right and License with respect thereto that will be effective upon the
Acceptance Date with respect to the Initial System, shall be *** .
Notwithstanding any other provision of this Agreement, IRORI shall not be
entitled to receive any consideration beyond the amount of the Initial System
Purchase Price in connection with such manufacture, delivery and installation,
except pursuant to Section 5.4.

        4.2 Payment Schedule. BMS shall pay the Initial System Purchase Price
upon the occurrence of the events set forth on Exhibit A (each such event, a
"Development Milestone") and in accordance with the progress payment schedule
set forth on Exhibit B attached. Each progress payment shall be made within 30
days after the satisfaction of the relevant Development Milestone as provided in
Section 2.2, without the need for IRORI to submit an invoice therefor to BMS.

        4.3 Mode of Payment; Taxes. BMS shall make all payments required under
this Agreement as directed by IRORI from time to time in U.S. Dollars. BMS shall
pay all federal, state and local sales, use, property, excise or other taxes
imposed on or with respect to the manufacture, delivery and installation of the
Systems, except taxes levied on IRORI's net income.

5. INTELLECTUAL PROPERTY; UPDATES.

        5.1 Invention Ownership. IRORI shall own all inventions, processes,
improvements, works of authorship, technology, ideas, data and know-how, whether
or not entitled to patent or copyright protection, that arise from IRORI's
performance of its obligation to manufacture the System (collectively,
"inventions"). The Parties agree that any Inventions shall not constitute "works
made for hire" under U.S. copyright law.

        5.2 Title Does Not Pass; Right and License. Notwithstanding any other
provision of this Agreement, title to any Software, Inventions and other
proprietary intellectual property of IRORI adapted or incorporated into the
System, Updates (as such term is defined herein) or Enhancements (collectively,
the "IRORI Intellectual property") shall not pass to BMS. Instead, to the extent
necessary, IRORI hereby grants BMS (effective upon the Acceptance Date with
respect to each System) a non-exclusive, paid-up worldwide right and license
during the term of this Agreement under the IRORI Intellectual Property to
operate each respective System purchased pursuant to this Agreement and exercise
its rights under this Agreement (collectively, the "Right and License"). BMS
shall not have the right to sublicense the Right and License without the prior
written consent of IRORI. BMS shall not have the right to assign the Right and

*** Portions of this page have been omitted pursuant to a request for
    Confidential Treatment and filed separately with the Commission

                                       8
<PAGE>   13
License except in connection with an assignment of all of BMS's rights and
obligations under this Agreement pursuant to, and in compliance with, Section
14.3.

        5.3 Updates. For a period of   ***   following the Acceptance Date with
respect to each System and at no cost to BMS, IRORI shall provide and
incorporate into such System, or grant BMS a Right and License to use, as the
case may be, all Updates to such System that are developed during such period.
Following such   ***   period, BMS shall have the right to purchase, or to be
granted a Right aid License to use, as the case may be, such Updates at IRORI's
standard commercial races therefor. Title to all Updates that are not IRORI
Intellectual Property shall pass to BMS upon their incorporation into the
System.

        5.4 Enhancements.

               (a) During the term of this Agreement, IRORI shall notify BMS
promptly after the development of any Enhancement not developed for BMS pursuant
to Section 5.4(b). Any such notice shall include a copy of the applicable
Enhancement Specifications. BMS shall have the right to purchase, or to obtain a
Right and License to use, as the case may be, any or all such Enhancements. In
the event that BMS wishes to purchase any such Enhancement or such Right and
License, BMS shall notify IRORI, and IRORI shall quote BMS a price therefor (the
"Enhancement Purchase Price").   ***     ***     ***. BMS may purchase such
Enhancement or a Right and License to use same, as the case may be, by
submitting a purchase order which is in a form mutually acceptable to the
parties, to the extent that such form is not inconsistent with the terms of this
Agreement, within    ***   .

               (b) In addition, BMS shall have the right to request, from time
to time, that IRORI develop Enhancements to meet Enhancement Specifications
proposed by BMS. IRORI shall not unreasonably refuse to develop any such
Enhancements. Promptly after any such request by BMS, the Development Committee
shall develop the Enhancement Specifications for the Enhancement. Promptly after
the Enhancement Specifications have been finalized, IRORI shall quote BMS the
Enhancement Purchase Price for the development and incorporation of such
Enhancement into the System (and, to the extent necessary a Right and License to
use same), *** , and shall provide a good faith estimate of the time IRORI will
require to develop such Enhancement. BMS may purchase such Enhancement or a
Right and License to use same, as the case may be, by submitting a purchase
order which is in a form mutually acceptable to the parties, to the extent that
such form is not inconsistent with the terms of this Agreement, *** . Following
receipt of any such purchase order, IRORI shall use its best commercial efforts
to deliver and incorporate into the System such Enhancement within the estimated
development period.

               (c) For a period of *** after IRORI's incorporation of any
Enhancement into the System, BMS shall have the right to test the System to
verify that the Enhancement conforms to the applicable Enhancement
Specifications (using the testing protocol developed by the

*** Portions of this page have been omitted pursuant to a request for
    Confidential Treatment and filed separately with the Commission

                                       9
<PAGE>   14

Development Committee). If BMS fails to notify IRORI that the Enhancement does
not conform to the applicable Enhancement Specifications prior to the end of
such *** period, then the Enhancement shall be deemed so to conform, and BMS
shall be deemed to have accepted it.

               (d) If such testing indicates that the Enhancement does not
conform to the Enhancement Specifications, then prior to the expiration of such
***   period referred to in Section 5.4(c), BMS shall notify IRORI of such
non-conformity in sufficient detail to allow IRORI to attempt to bring the
Enhancement into conformity with the applicable Enhancement Specifications.
During the   ***   period following receipt of any such notice, IRORI shall use
its best commercial efforts to bring the Enhancement into conformity with the
applicable Enhancement Specifications, and BMS shall allow IRORI's
representatives reasonable access to the System(s), during normal business
hours, for such purpose. If BMS reasonably determines, within   ***   after such
     ***   period, that the Enhancement does not conform to the applicable
Enhancement Specifications, then BMS shall be entitled to reject the Enhancement
by notice to IRORI. In the event of any such rejection, IRORI shall promptly
un-install the Enhancement and refund to BMS the entire amount of price
previously paid by BMS with respect thereto. If BMS fails to notify IRORI that
the Enhancement does not conform to the applicable Enhancement Specifications
prior to the end of such   ***   period, then the Enhancement shall be deemed so
to conform, and BMS shall be deemed to have accepted it.

               (e) Title to all Enhancements (i.e., to BMS's physical copies
thereof) that are not IRORI Intellectual Property shall pass to BMS upon BMS's
acceptance thereof.

               (f) IRORI shall submit an invoice for the Enhancement Purchase
Price to BMS upon delivery and installation of an Enhancement into the System.
All invoices shall be sent to the address specified on the BMS purchase order.
Payment of such invoices shall made within 45 days after receipt of an invoice
for such payment.

        5.5 Installation. The Parties shall cooperate in coordinating the
delivery and installation of any Updates or Enhancements.

        5.6 Source Code.

               (a) Within 180 days after the Effective Date and within 10 days
after the first day of each calendar quarter thereafter until the Source Code
Release Date (as herein defined), IRORI shall deposit with Data Securities
International, located in San Diego, California (the "Escrow Agent"), a copy of
the most current source code and any documentation (including drawings,
blueprints and other technical information) of and for the Software or otherwise
necessary or useful for the operation of the System, all pursuant to an escrow
agreement (the "Escrow Agreement") the terms and conditions of which are
acceptable to BMS. The Escrow Agreement shall provide, among other things, that
BMS shall have access to such source code, subject to the Right and License and
the other terms and conditions of this Agreement, if IRORI or any of its
Affiliates becomes the subject of any voluntary or involuntary proceeding, under
state or federal law, in the nature of bankruptcy, receivership or assignment
for the benefit

*** Portions of this page have been omitted pursuant to a request for
    Confidential Treatment and filed separately with the Commission

                                       10
<PAGE>   15

 of creditors which is not dismissed withal 60 days after the
institution, initiation or filing of such proceeding.

                      (b)    ***
                             ***
                             ***

               ***    . Notwithstanding any other provision of this Agreement,
BMS's rights under this Section 5.6(b) shall terminate upon any assignment of
its rights and obligations under this Agreement to a Third Party,

6. SUPPORT; TRAINING.

        6.1 Support and Maintenance. During the   ***   period following the
Acceptance Date with respect to each System, IRORI shall provide BMS with
customer and technical support in connection with BMS's use of such System, and
maintenance of such System, at no additional cost to BMS. After such   ***
period and during the remainder of the term of this Agreement, IRORI shall
provide BMS with customer and technical support in connection with BMS's use of
such System, and maintenance of such System, at IRORI's published commercial
rates therefor. Such support and maintenance shall include critical bug fixes,
reasonable assistance via telephone and fax, dial in via modem assistance,
receipt of any newsletter or other customer publications put out by IRORI and
on-site support.

        6.2 Training. For a period of   ***   after the Acceptance Date with
respect to each System, and for a period of   ***   following the installation
of any major Update or BMS's acceptance of any Enhancement, IRORI shall provide
training in the operation and maintenance thereof to BMS's employees at the
Facility, at no additional cost to BMS. BMS shall be responsible for all per
diem expenses incurred by its employees in connection with any such training.
The Parties shall cooperate in the scheduling of all such training.

7. SUPPLY AND PURCHASE.

                7.1 Initial Obligations.

               (a) On the Acceptance Date with respect to the Initial System,
BMS automatically shall be deemed to have ordered from IRORI an aggregate of
   ***   NanoKans, at a price of   ***   each, and IRORI shall be entitled to
submit to BMS an invoice therefor, in accordance with Section 7.9(a).

               (b) From time to time after the Acceptance Date with respect to
the Initial System, BMS shall deliver to IRORI resins to be loaded into the
NanoKans ordered by BMS pursuant to Section 7.1(a) (arty resins delivered by BMS
pursuant to this Section 7 collectively, the "BMS Resins"), accompanied by
instructions as to how many of such NanoKans should be loaded with such BMS
Resins and as to shipping and delivery of such NanoKans. Within 30

*** Portions of this page have been omitted pursuant to a request for
    Confidential Treatment and filed separately with the Commission

                                       11
<PAGE>   16

days after each such delivery of a sufficient quantity of BMS Resins, IRORI
shall load such NanoKans with such BMS Resins and deliver same to BMS in
accordance with Section 7.4, at no additional cost or expense to BMS. IRORI
acknowledges that all BMS Resins shall be proprietary to, and shall constitute
Confidential Information of, BMS.

                7.2 Requirements.

               (a) After BMS has ordered an aggregate of *** NanoKans pursuant
to Section 7.1, BMS shall purchase from IRORI, and IRORI shall supply to BMS,
NanoKans representing 100(degree)% of BMS's requirements for microreactors for
solid phase synthesis for use with the Systems. ***
                                                      ***
                      ***    . If IRORI has not supplied NanoKans to any Third
Party within such 12-month period, then such price shall be   ***   per NanoKan,
subject to adjustment commencing on January 1, 2001 (and on each January 1
thereafter) to reflect the aggregate change, if any, in the Consumer Price Index
(All Consumers, All Urban Areas), published by the U.S. Department of Labor,
during the period commencing on the immediately preceding January 1.

               (b) At any time following the seventh anniversary of the
Acceptance Date with respect to the Initial System, BMS shall have the right to
terminate its obligations under Section 7.2(a), or from time to time to reduce
the percentage of BMS's requirements for NanoKans that it is obligated to
purchase thereunder, by giving 180 days' prior notice to IRORI.

        7.3 Orders. Except as set forth in Section 7.1, BMS shall place orders
for NanoKans with IRORI, setting forth trade units, delivery dates and shipping
instructions with respect to each shipment, from time to time. IRORI shall
accept such orders from BMS. BMS's orders shall be made pursuant to a purchase
order which is in a form mutually acceptable to the parties, to the extent that
such form is not inconsistent with the terms of this Agreement. In conjunction
with the delivery of each such purchase order, BMS shall deliver to IRORI a
sufficient quantity of the BMS Resins with which the NanoKans ordered by BMS are
to be loaded.

        7.4 Delivery. IRORI shall deliver all NanoKans ordered by BMS pursuant
to Section 7.3 or 7.7 within   ***   of IRORI's receipt of BMS's purchase order
therefor (provided that BMS has delivered a sufficient quantity of the BMS
Resins as provided in Section 7.3 or 7.7, as applicable). All NanoKans delivered
pursuant to this Agreement shall be suitably packed for shipment by IRORI and
marked for shipment to the destination point indicated in BMS's purchase order.
All NanoKans will be delivered F.O.B. the shipping point designated by IRORI.
The shipping packaging shall be in accordance with good commercial practice with
respect to protection of the NanoKans during transportation. All shipping and
insurance costs, as well as any special packaging expenses, shall be paid by
BMS.

*** Portions of this page have been omitted pursuant to a request for
    Confidential Treatment and filed separately with the Commission

                                       12
<PAGE>   17

        7.5 Quality Control. IRORI shall conduct quality control testing of the
NanoKans prior to shipment in accordance with its customary quality control
procedures. IRORI shall retain records pertaining to such testing.

        7.6 Acceptance; Rejection.

               (a) BMS may test or cause to be tested the NanoKans supplied by
IRORI, using a random sampling methodology and otherwise in accordance with
BMS's customary procedures, within   ***   of receipt thereof by BMS or its
designee. BMS or its designee shall have the right to reject any shipment of
NanoKans made to it under this Agreement which does not meet the NanoKan
Specifications when received by BMS. All claims by BMS of non-conforming
NanoKans shall be deemed waived unless made by BMS in writing and received by
IRORI within such   ***   period. At IRORI's request and expense, BMS shall
return to IRORI or destroy, in accordance with IRORI's instructions, any
rejected shipment of NanoKans.

               (b) In the event that the parties are unable to agree as to
whether a shipment of NanoKans supplied by IRORI hereunder meet the NanoKan
Specifications, such question shall be submitted to an independent quality
control laboratory as the Parties may mutually agree upon. The findings of such
independent laboratory shall be binding upon the Parties, absent manifest error.
The cost of the independent quality control laboratory shall be borne by the
Party whose results are shown by such laboratory to have been incorrect.

               (c) In the event that IRORI concedes or the independent quality
control laboratory finds that a shipment of NanoKans does not comply with the
NanoKan Specifications, IRORI will, to the extent such shipment has not been
replaced pursuant to Section 7.7, remanufacture and deliver to BMS the same
quantity of NanoKans as contained in the shipment in question promptly after
BMS's delivery of replacement BMS Resins to be loaded into such NanoKans.

        7.7 Interim Replacement. During the pendency of any dispute concerning
the conformity of a shipment of NanoKans to the NanoKan Specifications, IRORI
shall replace the shipment under dispute, at the request of BMS, promptly after
BMS's delivery of replacement BMS Resins to be loaded into such NanoKans. Such
replacement NanoKans shall be ordered in accordance with Section 7.3 and shall
be invoiced by IRORI and paid for by BMS at the same price as the rejected
shipment of NanoKans was invoiced.

        7.8 Replacement of BMS Resins. In the event that any BMS Resins
delivered to IRORI pursuant to this Section 7 are damaged or destroyed due to
the negligence or willful misconduct of IRORI, or its employees or agents, then
IRORI shall reimburse BMS for any actual manufacturing costs incurred by BMS in
connection with the replacement of such BMS Resins.

        7.9 Invoicing; Payment.

*** Portions of this page have been omitted pursuant to a request for
    Confidential Treatment and filed separately with the Commission

                                       13
<PAGE>   18

               (a) IRORI shall submit an invoice to BMS upon shipment of
NanoKans ordered by BMS hereunder, whether pursuant to Section 7.1, 7.3 or 7.7.
All invoices shall be sent to the address specified on the BMS purchase order,
and each such invoice shall include any insurance, taxes or other costs incident
to the purchase or shipment initially paid by IRORI but to be borne by BMS
hereunder.

               (b) Payment of such invoices shall made within 45 days after
receipt of an invoice for such payment; provided, however, that BMS shall not be
required to pay any invoice with respect to any shipment of NanoKans that fails
to meet the NanoKan Specifications, but BMS shall be obligated to pay in full
for any rejected shipment of NanoKans that is subsequently determined to meet
the NanoKan Specifications; and provided, further, that the running of such
45-day period shall be tolled during the pendency of any dispute concerning the
conformity of a shipment of NanoKans to the NanoKan Specifications. In the event
that BMS pays for a shipment of NanoKans and subsequently rejects such shipment
in accordance with the terms of this Agreement, BMS shall be entitled to a
refund or credit equal to the amount paid with respect to such rejected shipment
and to reimbursement of the actual manufacturing costs incurred by BMS in
connection with a BMS Resins loaded into such NanoKans.

        7.10 Allocation.

               (a) Subject to Section 7.10(b), in the event that IRORI is unable
to supply all of BMS's requirements for NanoKans in accordance with Section 7.4,
due to force majeure or otherwise, IRORI shall allocate to   ***   of its
available NanoKans to BMS until IRORI has supplied all such NanoKans.

               (b) The Parties acknowledge and agree that during the term of
this Agreement IRORI may enter into a relationship with one Third Party that
shall be a strategic partner for purposes of this Section 7.10. If, at any time
when IRORI is unable to supply all of BMS's requirements for NanoKans, IRORI has
entered into a relationship with such a strategic partner, then IRORI shall
allocate   ***   of its available NanoKans between BMS and such partner, in
proportion to the quantity of NanoKans for which each of them has orders pending
at such time. IRORI shall promptly disclose BMS the identity of any such
strategic partner, if such strategic partner consents to such disclosure, in
which case IRORI shall have the right to disclose to such strategic partner the
existence (but not the specific financial terms) of BMS's relationship with
IRORI under this Agreement. In any event, in connection with any allocation
under this Section 7.10(b), IRORI shall notify BMS promptly of the identity of
any such strategic partner, if IRORI has not already done so.

        7.11 Right to Manufacture.

               (a) In the event of an Inability to Supply, BMS may elect either:
(i) to manufacture (or have manufactured) pursuant to Section 7.12 such quantity
of NanoKans that IRORI fails so to supply; or (ii) to assume full responsibility
for the supply of all of BMS's requirements for NanoKans under this Agreement.
For purposes of this Section 7, an "Inability

*** Portions of this page have been omitted pursuant to a request for
    Confidential Treatment and filed separately with the Commission

                                       14
<PAGE>   19

to Supply" shall mean: (X) with respect to any 60-day period, more than   ***
of the NanoKans to be delivered during such period were delivered more than 30
days after the respective delivery dates therefor; or (Y) with respect to any
six-month period, more than   ***   of the NanoKans to be delivered during such
period were delivered after the respective delivery dates therefor, provided, in
each case, that not more than   ***  , nor fewer than   ***   , NanoKans were to
be delivered during any 30-day period.

               (b) The remedy provided in this Section 7.11 shall be in addition
to any other remedies available to BMS under this Agreement, at law or in
equity. BMS's rights under this Section 7.11 shall not be affected in any way by
its waiver or failure to take action with respect to any previous event giving
rise to such right.

        7.12 BMS's Right to Manufacture. IRORI hereby grants to BMS, and BMS
hereby accepts, a license (the "Manufacturing License") under all necessary
IRORI patents and know-how to make or have made NanoKans for such of BMS's
requirements as BMS has elected pursuant to Section 7.11(a)(i) or (ii). Such
Manufacturing License shall be subject to all other terms and conditions of this
Agreement. In addition, BMS agrees not to exercise any of its rights under the
Manufacturing License except to the extent expressly permitted in Section
7.11(a). In such event: (i) IRORI shall provide to BMS (or its designee) copies
of all documentation within IRORI's control that is reasonably necessary for BMS
to manufacture (or have manufactured) NanoKans; (ii) IRORI shall provide such
technical assistance to BMS (or its designee) as is reasonably necessary to
enable BMS (or such of its Affiliates, Third Parties or designees as it may
designate) to manufacture NanoKans pursuant to the NanoKan Specifications,
including, without limitation, providing all information and know-how necessary
or useful for the construction of a resin-loading machine; (iii) BMS shall be
relieved of its obligation to purchase such quantities of NanoKans from IRORI,
to the extent that BMS has the right to exercise the Manufacturing License; and
(iv) IRORI shall reasonably cooperate with BMS to establish an alternative
supply, including sources of materials. In the event that BMS has NanoKans
manufactured by a Third Party, such Third Party shall enter into a
confidentiality agreement with IRORI to protect against the unauthorized use and
disclosure of IRORI's Confidential Information.

8. REPRESENTATIONS AND WARRANTIES; COVENANTS.

        8.1 Representations and Warranties of Both Parties. Each Party
represents and warrants to the other Party that: (i) it is free to enter into
this Agreement; (ii) in so doing, it will not violate my other agreement to
which it is a party; and (iii) it has taken all corporate action necessary to
authorize the execution and delivery of this Agreement and the performance of
its obligations under this Agreement.

        8.2 Representations and Warranties of IRORI. IRORI represents and
warrants to BMS that:

*** Portions of this page have been omitted pursuant to a request for
    Confidential Treatment and filed separately with the Commission

                                       15
<PAGE>   20

               (a) IRORI shall adhere to all governmental laws and regulations
applicable to the performance of its obligations under this Agreement.

               (b) IRORI shall have secured in a timely manner all permits or
licenses required in connection with the performance of its obligations under
this Agreement.

               (c) Neither IRORI's manufacture, delivery, installation and sale
of the System, nor its manufacture and sale of NanoKans, nor BMS's use of the
System or NanoKans shall infringe upon any U.S. or foreign Patent and shall not
violate, convict with or infringe upon any other rights of any Third Party.

               (d) No action; suit of claim, has been initiated, or threatened
in writing, against IRORI with respect to the intellectual property necessary
for it to perform its obligations under this Agreement (including, without
limitation, the IRORI Intellectual Property in existence as of the Effective
Date), or its right to enter into and perform its obligations under this
Agreement.

               (e) Each System and Enhancement shall be free from defects in
material and workmanship under normal use and service and, if operated and
maintained in accordance with IRORI's reasonable written instructions, shall
perform in accordance with the System Specifications or applicable Enhancement
Specifications, as the case may be, for a period of   ***  with respect thereto.

               (f) IRORI has not previously entered into or agreed to enter into
any agreements with any Third Parties with respect to the manufacture, delivery
and installation of any Systems or the manufacture and supply of NanoKans;
provided, however, that BMS acknowledges that IRORI is in advanced stages of
discussions with one Third Party which may become the strategic partner referred
to in Section 7.10(b) and/or the Permitted Purchaser (as such term is defined in
Section 9.1); and provided, further, that the Parties agree that in the event,
prior to the Effective Date, IRORI has entered into an agreement with any Third
Party pursuant to which it becomes such strategic partner and/or such Permitted
Purchaser, then IRORI shall not have the right to enter into any agreements with
any additional Third Parties pursuant to Section 7.10(b) and/or 9.1, as the case
may be.

        8.3 Limited Right of Repair. In connection with any breach of the
representations and warranties of IRORI set forth in Section 8.2(e) arising
after BMS's acceptance of a System or an Enhancement, as the case may be, IRORI
shall be entitled, at its sole cost and expense, to attempt to rectify, via
repair, replacement or Update, any such breach during a reasonable period of
time (but in no event greater than 60 days) after BMS provides IRORI notice of
such breach. During any such period when IRORI is diligently attempting to
rectify any such breach (or, if IRORI succeeds in so rectifying, thereafter),
BMS shall not pursue any remedy under this Agreement or otherwise at law or in
equity with respect to such breach. The Parties acknowledge and agree that any
forbearance by BMS pursuant to the preceding sentence shall not constitute a
waiver of any of BMS's rights in connection with such breach.

*** Portions of this page have been omitted pursuant to a request for
    Confidential Treatment and filed separately with the Commission

                                       16
<PAGE>   21

        8.4 Disclaimer of Warranty. EXCEPT AS SPECIFICALLY SET FORTH IN SECTIONS
8.1 AND 8.2, IRORI DOES NOT MAKE, AND HEREBY DISCLAIMS, ANY EXPRESS OR IMPLIED
WARRANTIES, INCLUDING BUT NOT LIMITED TO WARRANTIES OF DESIGN, MERCHANTABILITY
AND FITNESS FOR A PARTICULAR PURPOSE, OR ARISING FRONT A COURSE OF DEALING OR
USAGE OF TRADE PRACTICE, WITH RESPECT TO ANY SYSTEM OR NANOKANS PURCHASED BY BMS
UNDER THIS AGREEMENT.

        8.5 Covenants of BMS. BMS covenants to IRORI that BMS shall not create,
or attempt to create, by decompilation, reverse engineering or otherwise, the
System or any of its components, including without limitation the Software, or
NanoKans.

9. THIRD PARTIES.

        9.1 Semi-Exclusivity. During the period commencing on the Effective Date
and ending on the first anniversary of the Acceptance Date with respect to the
Initial System, IRORI shall not sell, license, lease or otherwise transfer any
interest in a System (or any functionally equivalent system,) to or for, or
operate a System (or any functionally equivalent system) for the benefit of,
more than one Third Party (such one Third Party, the "Permitted Purchaser"),
which shall be chosen at IRORI's sale discretion.

        9.2 Most Favored Nation.

               (a) If, during the period commencing on the Effective Date and
ending on the   ***   with respect to the Initial System (the "Protected
Period"), IRORI sells, or otherwise conveys full or substantially full title to,
a System (or any functionally equivalent system) to any Third Party at a price
less than the Initial System Purchase Price (a "Below-Price Sale"), then the
Initial System Purchase Price shall be adjusted, whether prospectively or
retroactively, to such lower price. IRORI shall promptly notify BMS of any
Below-Price Sale. If a Below-Price Sale occurs prior to BMS's payment in full of
the Initial System Purchase Price, then BMS's remaining payments against the
Initial System Purchase Price shall be adjusted accordingly. To the extent that
the amount of such remaining payments is insufficient to realize the full
adjustment to be made pursuant to this Section 9.2 or if a Below-Sale occurs
after BMS's payment in full of the Initial System Purchase Price, IRORI shall
refund the difference or the amount of such adjustment, as the case may be, to
BMS within 30 days after the date of IRORI's notice of such Below-Price Sale.

               (b) During the Protected Period, following any adjustment of the
Initial System Purchase Price pursuant to Section 9.2(a), if and as often as
IRORI sells, or otherwise conveys full or substantially full title to, a System
(or any functionally equivalent system,) to any Third Party at a price less than
the price to which the Initial System Purchase Price previously has been
adjusted, then the Initial System Purchase Price shall be further adjusted to
such lower price, in accordance with Section 9.2(a).

*** Portions of this page have been omitted pursuant to a request for
    Confidential Treatment and filed separately with the Commission

                                       17
<PAGE>   22

               (c) Notwithstanding the other provisions of this Section 9.2, the
Parties acknowledge and agree that if any Third Party purchases a System for no
less than   ***   and subsequently purchases a second System for no less than
   ***   , the purchase and sale of such second System shall not constitute a
Below-Price Sale.

        9.3 Audit Request.

               (a) Commencing on the Effective Date and until the sixth
anniversary of the Acceptance Date with respect to the Initial System, at the
request of BMS, IRORI and its Affiliates shall permit an independent certified
public accountant appointed by BMS, at reasonable times and upon reasonable
notice, to examine all relevant records and all other documents in the
possession or control of IRORI or its Affiliates as may be necessary: (i) to
verify IRORI's satisfaction of its obligations under Sections 9.1 and 9.2; or
(ii) to verify that IRORI is not in breach of its representation and warranty
under Section 8.2(f).

               (b) During the term of this Agreement and for a period of three
years thereafter, at the request of BMS, IRORI and its Affiliates shall permit
an independent certified public accountant appointed by BMS, at reasonable times
and upon reasonable notice, to examine all relevant records and all other
documents in the possession or control of IRORI or its Affiliates as may be
necessary: (i) to verify IRORI's satisfaction of its obligations under Section
7.10; or (ii) in connection with any assignment pursuant to Section 14.3(b), to
verify the correctness of any Assignment Fee charged by IRORI.

               (c) Said accountant shall not disclose to BMS the identity of any
Third party with which IRORI has a relationship. The results of any such
examination shall be made available to both Parties. BMS shall bear the full
cost of the performance of any such audit unless the results of such audit
indicate that IRORI is in default with respect to its obligations identified in
Section 9.3(a) or (b), in which event IRORI shall bear such cost.

10. INDEMNIFICATION.

        10.1 Obligation to Indemnify. Subject to Section 8.3, IRORI shall
defend, indemnify and hold BMS and its Affiliates, and each of their respective
directors, officers and employees (each, an "Indemnitee"), harmless from and
against any and all claims, suits or demands for liability, damages, losses,
costs and expenses (including the costs and expenses of attorneys and other
professionals) arising out of Third Party claims or suits resulting from a
breach of IRORI's representations and warranties set forth in Section 8.2, or
from any tort claims of personal injury (including death) or property damage
relating to or arising out of BMS's use of the System and/or NanoKans in
accordance with the System Specifications and/or the NanoKan Specifications, as
the case may be, and IRORI's written instructions.

        10.2 Notice. In the event that any Indemnitee is seeking indemnification
under Section 10.1, such Indemnitee shall inform IRORI of a claim as soon as
reasonably practicable after it receives notice of the claim, shall permit IRORI
to assume direction and control of the defense of the claim (including the sole
right to settle the claim at IRORI's sole discretion,

*** Portions of this page have been omitted pursuant to a request for
    Confidential Treatment and filed separately with the Commission

                                       18
<PAGE>   23

provided that such settlement does not materially adversely affect any rights
of, or impose any obligation on, the Indemnitee) with legal counsel selected by
IRORI and reasonably acceptable to BMS, and shall cooperate as requested (at the
expense of the IRORI) in the defense of the claim.

        10.3 Complete Indemnification. As the Parties intend complete
indemnification, all costs and expenses incurred by an Indemnitee in connection
with enforcement of this Section 10 shall also be reimbursed by IRORI.

        10.4 Insurance. During the term of this Agreement and for a period of 10
years thereafter, IRORI shall maintain basic comprehensive general liability and
products liability insurance (including contractual liability coverage on
IRORI's indemnification obligations under this Agreement) with respect to the
work it performs and the products it manufactures and sells under this Agreement
substantially consistent with the insurance coverage described on Exhibit C,
which insurance shall designate BMS as an additional insured and shall pay the
premiums due thereunder. The terms and conditions of such insurance policy and
any and all amendments thereto, as well as the amount insured, shall be
submitted for reasonable approval to BMS, and BMS shall receive a copy of any
such policy and amendments thereto.

        10.5 Partial Limitation on IRORI Indemnity. In no event shall IRORI's
liability under this Section 10 with respect to Third Party claims or suits
resulting from a breach of IRORI's representations and warranties set forth in
Section 8.2 exceed the total Purchase Price paid by BMS under this Agreement.

11. CONFIDENTIALITY.

        11.1 Confidential Information. Except as expressly provided herein, the
Parties agree that, during the term of this Agreement and for eight years
thereafter, the receiving Party shall not publish or otherwise disclose and
shall not use for any purpose any information furnished to it by the other Party
pursuant to this Agreement which, if disclosed in tangible form, is marked
"Confidential" or with other similar designation to indicate its confidential or
proprietary nature or, if disclosed orally, is indicated as confidential or
proprietary in writing by the disclosing Patty within a reasonable time after
such disclosure (collectively, "Confidential Information"). Notwithstanding the
foregoing, Confidential Information shall not include information that, in each
case as demonstrated by written documentation:

               (a) was already known to the receiving Party, other than under an
obligation of confidentiality, at the time of disclosure;

               (b) was generally available to the public or otherwise part of
the public domain at the time of its disclosure to the receiving Party;

               (c) became generally available to the public or otherwise part of
the public domain after its disclosure and other than through any act or
omission of the receiving Party in breach of this Agreement; or

                                       19
<PAGE>   24

               (d) was subsequently lawfully disclosed to the receiving Party by
a Third Party or developed by the receiving Party without reference to any
information or materials disclosed by the disclosing Party.

        11.2 Permitted Disclosures. Notwithstanding the provisions of Section
11.1, each Party may disclose the other Party's Confidential Information to the
extent such disclosure is reasonably necessary to exercise the rights granted to
it under this Agreement or to comply with applicable laws and regulations,
provided that if a Party is required to make any such disclosure of the other
Party's Confidential Information, to the extent it may legally do so, it will
give reasonable advance notice to the latter Party of such disclosure and will
use its reasonable efforts to limit the scope of such disclosure to only that
information which it is necessary to disclose and to secure confidential
treatment of such information prior to its disclosure. If the Party whose
Confidential Information is to be disclosed has not filed a patent application
with respect to such Confidential Information, it may require the other Party to
delay the proposed disclosure (to the extent the disclosing Party may legally do
so) for up to 90 days, to allow for the filing of such as application.

        11.3 Remedies. Each Party shall be entitled, in addition to any other
right or remedy it may have, at law or in equity, to temporary, preliminary and
permanent injunctions, without the posting of any bond or other security,
enjoining or restraining the other Party and its Affiliates from any violation
or threatened violation of this Section 11.

12. TERM; TERMINATION.

        12.1 Term. The term of this Agreement shall commence as of the Effective
Date and shall expire upon the termination, pursuant to Section 7.2(b), of BMS's
obligation to purchase NanoKans from IRORI, unless sooner terminated in
accordance with this Section 12.

        12.2 Termination by BMS. BMS shall have the right to terminate this
Agreement at any time prior to the Acceptance Date with respect to the Initial
System, upon notice to IRORI, without further obligation to IRORI except as
provided in this Section 12.2 and in Section 12.4(b). In conjunction with BMS's
giving of any such notice, BMS shall pay the next payment of the Initial System
Purchase Price that would have accrued under Section 4.2 if BMS had not
terminated this Agreement. In addition, following any such termination, IRORI
shall be entitled to retain all payments of the Initial System Purchase Price
that BMS shall have made prior to the date of any such notice, and BMS shall
remain liable to IRORI for all payments of the Initial System Purchase Price
that shall have accrued but shall not have been paid prior to the date of any
such notice.

        12.3 Breach.

               (a) Subject to Section 12.3(b), failure by either Party to comply
with any of the material obligations contained in this Agreement shall entitle
the other Party to give to the Party in default notice specifying the nature of
the default and requiring it to cure such default. If such default is not cured
within 30 days after the receipt of such notice (or, if such default reasonably
cannot be cured within such 30-day period, if the Party in default does not
commence and diligently continue actions to cure such default), the notifying
Party shall be entitled, without

                                       20
<PAGE>   25

prejudice to any of its other rights conferred on it by this Agreement and in
addition to any other remedies available to it at law or in equity, to terminate
this Agreement by giving further written notice, to take effect immediately upon
delivery thereof. The right of either Party to terminate this Agreement, as
provided in this Section 12.3(a), shall not be affected in any way by its waiver
or failure to take action with respect to any previous default.

               (b) Notwithstanding Section 12.3(a), BMS shall not have the right
to terminate this Agreement with respect to:

                      (i) Any failure of IRORI to satisfy a Development
Milestone or any failure of a System to conform to the System Specifications
until IRORI has been given an opportunity to rectify such failure, as provided
in Sections 2.2 and 2.3, as the case may be;

                      (ii) Any failure of as Enhancement to conform to the
applicable Enhancement Specifications;

                      (iii) Any alleged failure of NanoKans supplied hereunder
to conform to the NanoKan Specifications;

                      (iv) Any Inability to Supply;

                      (v) Any breach of the representations and warranties of
IRORI set forth in Section 8.2(e) arising after BMS's acceptance of a System
unless IRORI has been given an opportunity to rectify such breach, as provided
in Section 8.3; or

                      (vi) Any breach of the representations and warranties of
IRORI set forth in Section 8.2(e) with respect to any Enhancement.

        12.4 Effect of Termination.

               (a) Following the expiration of the term of this Agreement
pursuant to Section 12.1 due to the termination, pursuant to Section 7.2(b), of
BMS's obligation to purchase NanoKans from IRORI, the Right and License shall
become perpetual.

               (b) Following the termination of this Agreement by BMS pursuant
to Section 12.2, BMS shall return to IRORI the Initial System, or any components
thereof, to the extent that same shall have been delivered to BMS prior to the
effective date of such termination, at BMS's sole cost and expense. Neither
Party thereafter shall have any obligation to the other, except under Section 11
and BMS's obligation to make payment of any portion of the Initial System
Purchase Price that shall have accrued as of the date of such termination, and
each Party shall return to the other all Confidential Information disclosed to
such Party by the other Party (and all copies, analyses, derivatives,
reflections and physical manifestations thereof); provided that each Party shall
have the right to retain one copy for archival purposes only.

               (c) Following the termination of this Agreement by IRORI pursuant
to Section 12.3: (i) BMS shall return to IRORI all Systems and Enhancements
which it has not accepted prior to the effective date of any such termination,
at BMS's sole cost and expense; (ii) BMS shall be entitled to retain all Systems
and Enhancements which it has accepted and paid the

                                       21
<PAGE>   26

Purchase Price for prior to the effective date of any such termination; (iii)
the light and License with respect to the Systems and Enhancements referred to
in clause (ii) shall become perpetual; and (iv) IRORI shall be entitled to
retain all payments of Purchase Price made by BMS prior to the effective date of
such termination.

               (d) following the termination of this Agreement by BMS pursuant
to Section 12.3: (i) BMS shall be entitled to retain all Systems and
Enhancements which have been delivered to it prior to the effective date of any
such termination, to the extent that BMS subsequently accepts and pays for same
(including by offsetting any such payment obligations against BMS's claims
against IRORI for damages); (ii) BMS shall be entitled to return to IRORI all
Systems and Enhancements which have been delivered to BMS prior to the effective
date of any such termination that BMS subsequently rejects; (iii) the Right and
License with respect to the Systems and Enhancements referred to in clause (i)
shall become perpetual; and (iv) the Manufacturing License shall become
perpetual.

        12.5 Accrued Rights, Surviving Obligations.

               (a) Termination, relinquishment or expiration of this Agreement
for any reason shall be without prejudice to any rights which shall have accrued
to the benefit of either Party prior to such termination, relinquishment or
expiration. Such termination, relinquishment or expiration shall not relieve
either Party from obligations which are expressly indicated to survive
termination or expiration of this Agreement.

               (b) Except as provided in Section 12.4(b), all of the Parties'
rights and obligations under Sections 2.4, 4.3, 5.1, 5.2, 5.4(e), the last
sentence of Section 7.1(b), 7.6, 7.7, 7.8, 8, 9.3, 10, 11, 12.4, 14.1, 14.3,
14.9, 14.14, 14.15 and 14.16 shall survive expiration, termination or
relinquishment of this Agreement.

13. FORCE MAJEURE.

        13.1 Events of Force Majeure. Neither Party shall be held liable or
responsible to the other Party or be deemed to be in default under or in breach
of any provision of this Agreement (other than, any obligation to pay money) far
failure or delay in fulfilling or performing any obligation of this Agreement
when such failure or delay is due to force majeure, and without the fault or
negligence of the Party so failing or delaying. For purposes of this Agreement,
force majeure shall be defined as causes beyond the control of the Party,
including, without limitation, acts of God; acts, regulations, or laws of any
government; war; civil commotion; destruction of production facilities or
materials by fire, flood, earthquake, explosion or storm; labor disturbances;
epidemic; and failure of public utilities or common carriers. In such event BMS
or IRORI, as the case may be, shall immediately notify the other Party of such
inability and of the period for which such inability is expected to continue.
The Party giving such notice shall thereupon be excused from such of its
obligations under this Agreement (other than any obligation to pay money) as it
is thereby disabled from performing for so long as it is so disabled and the 30
days thereafter. However, the Party giving such notice shall use all reasonable
efforts to remedy such inability as soon as reasonably possible or seek an
alternative arrangement during the period of such inability.

                                       22
<PAGE>   27

14. MISCELLANEOUS.

        14.1 Non-Solicitation. During the period commencing on the Effective
Date and ending on the 18-month anniversary of the Acceptance Date with respect
to the Initial System (or, if BMS has ordered a Second System by such Acceptance
Date and subsequently accepts the Second System, the 18-month anniversary of the
Acceptance Date with respect to the Second System), neither Party shall solicit,
induce, encourage or attempt to induce or encourage any employee of the other
Party to terminate his or her employment with such other Party or to breach any
other obligation to such other Party.

        14.2 Relationship of Parties. Nothing in this Agreement is intended or
shall be deemed to constitute a partnership, agency, employer-employee or joint
venture relationship between the Parties. No Party shall incur any debts or make
any commitments for the other, except to the extent, if at all, specifically
provided herein.

        14.3 Assignment.

               (a) This Agreement may not be assigned, in whole or in part, by
IRORI without the prior written consent of BMS.

               (b) BMS may assign its rights and obligations under this
Agreement to a Third Party provided that: (i) such assignment is of all of such
rights and obligations; (ii) such Third Party agrees in writing to be bound by
the terms of this Agreement as if it were a party hereto; and (iii) IRORI is
paid the applicable Assignment Fee in connection with such assignment. For
purposes of this Section 14.3(b), "Assignment Fee" shall mean: (X )   ***
if, on the effective date of such assignment, IRORI has sold, licensed, leased
or otherwise disposed of any interest in a System (or any functionally
equivalent system) to or for, or operated a System (or any functionally
equivalent system) for the benefit of,     ***    or fewer Third Parties, and
(Y)    ***    if, on such date, IRORI has sold, licensed, leased or otherwise
disposed of any interest in a System (or any functionally equivalent system) to
or for, or operated a System (or any functionally equivalent system) for the
benefit of, more than    ***   Third Parties.

               (c) Notwithstanding Sections 14.3(a) and (b), either Party may
assign its respective rights and transfer its respective duties hereunder,
without the consent of the other Party, to any assignee of all or substantially
all of its respective business or in the event of its respective merger,
consolidation or similar transaction.

               (d) Any assignment not in accordance with this Section 14.3 shall
be void.

        14.4 Binding Effect. This Agreement shall be binding upon the successors
and permitted assigns of the Parties, and the name of a Party appearing herein
shall be deemed to include the names of such Parties successors and permitted
assigns to the extent necessary to carry out the intent of this Agreement.

*** Portions of this page have been omitted pursuant to a request for
    Confidential Treatment and filed separately with the Commission

                                       23
<PAGE>   28

        14.5 Further Actions. Each Party agrees to execute, acknowledge and
deliver such further instruments, and to do all such other acts, as may be
necessary or appropriate in order to carry out the proposes and intent of this
Agreement, .

        14.6 Costs and Expenses. Except as otherwise expressly provided in this
Agreement, each Party shall bear all costs and expenses associated with the
performance of such Party's obligations under this Agreement.

        14.7 Inconsistency. If there is any inconsistency between the provisions
of this Agreement and any other document passing between the Parties, the
provisions of this Agreement shall control and be determinative.

        14.8 Notice. Any notice, request or other communication required or
permitted to be given under or in connection with this Agreement shall be deemed
to have been sufficiently given if in writing and personally delivered or sent
by registered or certified mail, postage prepaid (return receipt requested),
facsimile transmission (receipt verified) or express courier service (signature
required), to the Party for which such notice is intended, at the address set
forth for such Party below:

               (a) In the case of BMS, to:

                      Bristol-Myers Squibb Company
                      P.O. Box 4000
                      Route 206 & Province Line Road
                      Princeton, New Jersey 08543-4000
                      Attention: Vice President & Senior Counsel
                                 Pharmaceutical Research Institute
                                 and Worldwide Strategic Business
                                 Development
                      Facsimile No.: (609) 252-4232

               (b) In the case of IRORI, to:

                      IRORI
                      11149 North Torrey Pines Road
                      La Jolla, California 92037-1030
                      Attention: President
                      Facsimile No.: (619) 546-3083

or to such other address for such Party as it shall have specified by like
notice to the other Party, provided that notices of a change of address shall be
effective only upon receipt thereof. If sent by facsimile transmission or
express courier service, the date of mailing or transmission shall be deemed to
be the date on which such notice or request was given. If sent by registered or
certified mail, the third business day after the date of mailing shall be deemed
to be the date on which such notice or request was given.

                                       24
<PAGE>   29

        14.9 Use of Name. Except as otherwise provided herein, neither Party
shall have any right, express or implied, to use in any manner the name or other
designation of the other Party or any other trade name or trademark of the other
Party for any purpose.

        14.10 Public Announcements. Neither Party shall make any public
announcement concerning this Agreement or the subject matter hereof without the
prior written consent of the other, which shall not be unreasonably withheld. In
the event of a required public announcement, the Party making such announcement
shall provide the other Party with a copy of the proposed text prior to such
announcement sufficiently in advance of the scheduled release of such
announcement to afford such other Party a reasonable opportunity to review and
comment upon the proposed text.

        14.11 Waiver. A waiver by either Party of any of the terms and
conditions of this Agreement in any instance shall not be deemed or construed to
be a waiver of such term or condition for the future, or of any subsequent
breach hereof. All rights, remedies, undertakings, obligations and agreements
contained in this Agreement shall be cumulative and none of them shall be in
limitation of any other remedy, right, undertaking, obligation or agreement of
either Party.

        14.12 Severability. When possible, each provision of this Agreement will
be interpreted in such manner as to be effective and valid under applicable law,
but if any provision of this Agreement is held to be prohibited by or invalid
under applicable law, such provision will be ineffective only to the extent of
such prohibition or invalidity, without invalidating the remainder of this
Agreement. In such event, the Parties agree to substitute a valid and
enforceable provision therefor which, as nearly as possible, achieves the
desired economic effect and mutual understanding of the Parties under this
Agreement.

        14.13 Amendment. No amendment, modification or supplement of any
provisions of this Agreement shall be valid or effective unless made in writing
and signed by a duly authorized officer of each Party.

        14.14 Governing Law. This Agreement shall be governed by and interpreted
in accordance with the laws of the State of New York, without regard to its
choice of law principles.

        14.15 Arbitration.

               (a) Except as otherwise provided in this Agreement, any dispute
arising out of or relating to any provisions of this Agreement shall be finally
settled by arbitration to be held in San Diego, California, under the auspices
and then current commercial arbitration rules of the American Arbitration
Association. Such arbitration shall be conducted by three arbitrators appointed
according to said rules. The Parties shall instruct such arbitrators to render a
determination of any such dispute within 30 days after their appointment.
Judgment upon any award rendered may be entered in any court having
jurisdiction, or application may be made to such court for a judicial acceptance
of the award and an order of enforcement, as the case may be.

                                       25
<PAGE>   30

               (b) Section 14.15(a) shall not prohibit a Party from seeking
injunctive relies from a court of competent jurisdiction in the event of a
breach or prospective breach of this Agreement by the other Party which would
cause irreparable harm to the first Party or under Section 11.

        14.16 Limitation on Liability. NOTWITHSTANDING ANY OTHER PROVISION OF
THIS AGREEMENT, UNDER NO CIRCUMSTANCES SHALL IRORI BE LIABLE UNDER THIS
AGREEMENT FOR ANY INDIRECT, CONSEQUENTIAL, SPECIAL OR EXCEPTIONAL DAMAGES
(INCLUDING, WITHOUT LIMITATION, LOSS OF PROFITS OR REVENUES).

        14.17 Entire Agreement. This Agreement sets forth the entire agreement
and understanding between the Parties as to the subject matter hereof and merges
all prior discussions and negotiations between them, and neither of the Parties
shall be bound by any conditions, definitions, warranties, understandings or
representations with respect to such subject matter other than as expressly
provided herein or as duly set forth on or subsequent to the date hereof in
writing and signed by a proper and duly authorized officer or representative of
the Party to be bound thereby.

        14.18 Counterparts. This Agreement may be executed simultaneously in any
number of counterparts, any one of which need not contain the signature of more
than one Party but all such counterparts taken together shall constitute one and
the same agreement.

        14.19 Descriptive Headings. The descriptive headings of this Agreement
are for convenience only, and shall be of no force or effect in construing or
interpreting any of the provisions of this Agreement.

                                       ***

                                       26
<PAGE>   31

        IN WITNESS WHEREOF, each of the Parties has caused this Strategic
Alliance Agreement to be executed by its duly authorized officer as of the day
and year first above written.

                                        BRISTOL-MYERS SQUIBB COMPANY

                                        By: /s/ Charles Linzner
                                            ------------------------------------

                                        Name: Charles Linzner
                                              ----------------------------------

                                        Title: Vice President & Senior Counsel
                                               ---------------------------------

                                        IRORI

                                        By: /s/ Riccardo Pigliucci
                                            ------------------------------------

                                        Name: Riccardo Pigliucci
                                              ----------------------------------

                                        Title: Chief Executive Officer
                                               ---------------------------------

<PAGE>   32

                                    EXHIBIT A

                SYSTEM AND NANOKAN SPECIFICATIONS AND MILESTONES

                                       ***
                                       ***
                                       ***

*** Portions of this page have been omitted pursuant to a request for
    Confidential Treatment and filed separately with the Commission

                                   Exhibit A-1
<PAGE>   33

                                    EXHIBIT B

                            PROGRESS PAYMENT SCHEDULE

                                       ***
                                       ***
                                       ***

*** Portions of this page have been omitted pursuant to a request for
    Confidential Treatment and filed separately with the Commission

                                   Exhibit B-1
<PAGE>   34

                                    EXHIBIT C

                        DESCRIPTION OF INSURANCE COVERAGE

<TABLE>
<CAPTION>
               TYPE OF COVERAGE                       PRIMARY COVERAGE            UMBRELLA
<S>                                                   <C>                     <C>
Comprehensive General Liability (including               $2,000,000*             $9,000,000
Contractual Liability)
Personal & Advertising Injury                            $1,000,000           (incl. in above)
Products and Completed Operations                         2,000,000*             $9,000,000
</TABLE>

*  $1,000,000 per occurrence and $2,000,000 in the aggregate.

                                   Exhibit C-1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00009-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00009-of-00352.parquet"}]]